🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chūōku
Clinical trial register · Japan

Clinical Trials in Chūōku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2472 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
2472
Studies in scope
all four open statuses
1255
Recruiting now
open to new participants
347
Lead sponsors
across recruiting studies
Top sites
Fukuoka 550 Nagoya 510 Sapporo 402 Tokyo 363 Osaka 345
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca92 Eli Lilly and Company35 Daiichi Sankyo14 Janssen Research & Development, LLC13 EMD Serono Research & Development Institute, Inc.7
Site location
Fukuoka550 Nagoya510 Sapporo402 Tokyo363 Osaka345
All 929 locations
Target enrolment
to

Trials with a site in Chūōku

202 of 2472 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Chūōku, Kashiwa, Kōtō City, Kyoto
2024-03-05
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kōtoku, Minatoku, Nagaizumi-cho
2024-02-27
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
DrugsValemetostat Tosylate·Datopotamab Deruxtecan·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 1
210
Chūōku, Fukuoka, Kashiwa, Kōtoku, Nagoya, Osaka, Ōsaka-sayama, Shizuoka
2024-02-22
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Chūōku, Fujieda-shi, Fukuoka, Kitakyushu, Kobe, Kure-shi, Kyoto, Minoh
2024-02-21
Recruiting
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
NCT06130553Advanced Solid Tumors That Are MTAP Deficient
DrugsAZD3470·Datopotamab Deruxtecan
AstraZeneca
Phase 1/2
334
Chūōku, Kashiwa
2024-01-18
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka
2023-12-29
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugVolrustomig
AstraZeneca
Phase 3
1,145
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe
2023-12-14
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Onivyde·Nanoliposomal Irinotecan·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
Chūōku, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi
2023-12-13
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab Deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi
2023-11-23
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsXeloda·Datopotamab Deruxtecan·Epirubicin·Olaparib
AstraZeneca
Phase 3
1,902
Akashi-shi, Akita, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu
2023-11-14
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
Chūōku, Fujisawa-shi, Fukui-shi, Fukuoka, Hashima-gun, Kamakura-shi, Kasuga-shi, Kawaguchi-shi
2023-11-07
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Hirakata-shi, Hiroshima, Iruma-Gun
2023-10-05
Recruiting
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsTRK-950·Ramucirumab·Paclitaxel
Toray Industries, Inc
Phase 2
146
Yokohama, Shinden, Nagaizumi-cho, Chūōku, Kashiwa, Kōtoku
2023-10-04
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Chūōku, Hirakata-shi, Kashiwa, Kōtoku, Osaka, Ōsaka-sayama, Sendai
2023-08-18
Active, closed
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
NCT05771480Biliary Tract Cancer
DrugsAlbumin-Bound Paclitaxel·Serplulimab·Durvalumab·Oxaliplatin
AstraZeneca
Phase 3
142
Chūōku, Kanazawa, Kashiwa, Kyoto, Osaka, Sendai, Ube, Wakayama
2023-08-16
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
DrugIza-bren
SystImmune Inc.
Phase 1
540
Chūōku
2023-08-08
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443Moderate to Severe Asthma
DrugsIcs-Laba·Povorcitinib
Incyte Corporation
Phase 2
247
Chūōku, Fukuoka, Kishiwada, Kitakyushu-shi, Mizunami-shi, Osaka, Sakaide-shi, Sapporo
2023-07-11
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
392
Chūōku, Kashiwa, Kōtoku
2023-07-11
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
DrugsSacituzumab Govitecan·Nab-paclitaxel·Capecitabine·Paclitaxel
Gilead Sciences
Phase 3
654
Aichi, Aoba-ku, Bunkyō City, Chiba, Chūōku, Ehime, Fukushima, Kagoshima
2023-05-08
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine
AstraZeneca
Phase 2
294
Chūōku, Kashiwa, Yokohama
2023-04-24
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi
2023-03-31
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig
AstraZeneca
Phase 2
163
Chūōku, Kashiwa, Sunto-gun
2023-01-16
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab Deruxtecan·Durvalumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 3
1,350
Bunkyō City, Chūōku, Hamamatsu, Hidaka-shi, Hirosaki-shi, Hiroshima, Kumamoto, Nagoya
2022-12-29
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200Atrial Fibrillation (AF)
DrugAbelacimab
Anthos Therapeutics, Inc.
Phase 3
2,500
Akashi, Chikushino-shi, Chūōku, Funabashi-Shi, Hamada-shi, Hamamatsu, Himeji-Shi, Imabari
2022-12-27
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·5-FU·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Chūōku, Kashiwa, Kōtoku
2022-12-21
Active, closed
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
470
Amagasaki-shi, Bunkyō City, Chiba, Chuo-shi, Chūōku, Fukuoka, Hiroshima, Hitachi-Naka
2022-12-13
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
DrugsDatopotamab Deruxtecan·Durvalumab·Capecitabine·Pembrolizumab
AstraZeneca
Phase 3
1,174
Akashi-shi, Chiba, Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kashiwa
2022-11-28
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
15,374
Chūōku, Fukuoka, Izumisano, Kyoto, Minatoku, Onga-gun, Osaka, Uji
2022-10-11
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Fukuyama, Gifu, Hachioji-shi
2022-10-04
Active, closed
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327Systemic Lupus Erythematosus
DrugEnpatoran
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
Asahikawa-shi, Chiba, Chūōku, Hiroshima, Kagoshima, Kawagoe-shi, Kita-gun, Sapporo
2022-09-16
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsCeralasertib·Durvalumab·Docetaxel
AstraZeneca
Phase 3
594
Bunkyō City, Chūōku, Kōtoku, Kurashiki-shi, Kurume-shi, Matsuyama, Nagoya, Niigata
2022-09-15
Active, closed
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510Colitis, Ulcerative
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
418
Bunkyō City, Chūōku, Fujiidera-shi, Fukuoka, Fukushima, Hachinohe, Hachiōji, Hamamatsu
2022-09-13
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Xeloda
AstraZeneca
Phase 2
454
Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi
2022-09-06
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
Chūōku, Himeji, Hirakata, Kanagawa, Kurashiki, Kurume, Matsusaka, Niigata
2022-08-05
Active, closed
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030Colorectal Cancer
DrugsM9140·Folinic acid·5-FU·Adrucil
EMD Serono Research & Development Institute, Inc.
Phase 1
220
Chūōku, Kashiwa-shi, Kitaadachi-gun, Kōtoku, Nagoya, Osakasayama-shi, Sunto-gun, Yokohama
2022-08-04
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
341
Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa
2022-08-03
Active, closed
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286Triple Negative Breast Cancer, PD-L1 Positive
DrugsAbraxane·Taxol·Sacituzumab Govitecan·Nab-paclitaxel
Gilead Sciences
Phase 3
443
Aichi, Aoba-ku, Bunkyō City, Chūōku, Ehime, Fukushima, Inamachi, Kagoshima
2022-07-25
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine
Gilead Sciences
Phase 3
623
Aichi, Bunkyō City, Chūōku, Ehime, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2022-07-20
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
DrugsEribulin·Datopotamab Deruxtecan·Nab-paclitaxel·Capecitabine
AstraZeneca
Phase 3
644
Chūōku, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun, Kōtoku
2022-05-16
Recruiting
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705Breast Cancer
DrugsAnastrozole, Exemestane·Imlunestrant·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 1
260
Chūōku, Kōtō City, Kyoto, Nagoya
2022-05-11
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Chūōku, Fukuoka, Hiroshima, Kashihara-shi, Kashiwa, Kumamoto, Mitaka-shi, Morioka
2022-03-28
Active, closed
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
NCT05280470Extensive-stage Small-cell Lung Cancer
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 2
187
Chūōku, Kashiwa, Kōtoku, Nagaizumi-chō, Osaka, Ōsaka-sayama, Yokohama
2022-03-09
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3
Janssen Research & Development, LLC
Phase 3
350
Bunkyō City, Chūōku, Fukui-ken, Fukuoka, Fukuyama, Gamagōri, Gunma, Hachinohe
2022-01-19
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
454
Chūōku, Fukuoka, Kashiwa, Matsuyama, Niigata, Okayama, Osaka, Sakai
2021-10-28
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
DrugsPertuzumab·Trastuzumab deruxtecan·Doxorubicin·Trastuzumab
AstraZeneca
Phase 3
927
Chūōku, Hidaka-shi, Hiroshima, Kawasaki-shi, Kōtoku, Nagoya, Ota-shi, Shinjuku-ku
2021-10-25
Active, closed
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
NCT05101096Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1/2
135
Aichi, Akita, Aoba-ku, Aomori, Asahi-ku, Bunkyō City, Chiba, Chūōku
2021-10-20
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
DrugsPalacaparib·Saruparib·Rilvegostomig
AstraZeneca
Phase 1/2
460
Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun
2021-10-18
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
DrugsVinorelbine·Eribulin·Datopotamab Deruxtecan·Capecitabine
AstraZeneca
Phase 3
732
Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun
2021-10-18
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
DrugAZD7789
AstraZeneca
Phase 1/2
136
Chūōku, Kashiwa
2021-09-28
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsRiabni·Ruxience·Venclyxto·Truxima
Loxo Oncology, Inc.
Phase 3
600
Bunkyō City, Chiba-Ken, Chūō, Chūōku, Fukui, Kōtō City, Kyoto, Nankoku
2021-09-20
Active, closed
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866Alzheimer Disease
DrugDonanemab
Eli Lilly and Company
Phase 3
2,996
Bunkyō City, Chūōku, Hachiōji, Osaka, Ōbu, Shinjuku, Shinjuku-ku, Suita-shi
2021-08-27
Active, closed
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
NCT06532344Metastatic Pancreatic Cancer
DrugsMagrolimab·Levofolinate·Fluorouracil·Irinotecan
Ono Pharmaceutical Co., Ltd.
Phase 1
32
Kashiwa-shi, Yokohama, Hamamatsu, Bunkyō-Ku, Koto-ku, Mitaka-shi, Shinjuku-Ku, Chūōku
2021-07-30
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib
AstraZeneca
Phase 3
315
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama
2021-06-30
Active, closed
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
367
Chiba, Chūōku, Hamamatsu, Hiroshima, Itabashi-ku, Kita-gun, Kitakyushu-shi, Meguro-ku
2021-06-08
Active, closed
STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation
NCT04428944Atrial Fibrillation
McGill University Health Centre/Research Institute of the McGill University Health Centre
Not applicable
617
Koshigaya, Bunkyo City, Chūōku, Tokyo
2021-06-01
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel
Daiichi Sankyo
Phase 3
490
Nagoya, Chūōku, Gifu, Kashiwa, Kobe, Kochi, Kōtoku, Matsuyama
2021-05-21
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
DrugsCapivasertib·Ribociclib·Abemaciclib·Palbociclib
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab
AstraZeneca
Phase 3
1,157
Akashi-shi, Aomori, Bunkyō City, Chiba, Chūōku, Fukushima, Hidaka-shi, Hiroshima
2021-04-26
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
DrugSurovatamig
AstraZeneca
Phase 1
226
Chūōku, Kōtoku, Nagoya, Yamagata
2021-03-02
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Palbociclib
AstraZeneca
Phase 3
1,370
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Isehara-shi, Kitaadachi-gun, Kōtoku, Kumamoto
2021-01-28
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
Chūōku, Kashiwa, Suita-shi
2020-12-30
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Docetaxel
Daiichi Sankyo
Phase 3
605
Akashi, Chūōku, Fukuoka, Hidaka, Hirakata, Kanazawa, Kashiwa, Kōtoku
2020-12-21
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Akashi, Chūōku, Fukuoka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kōtoku
2020-12-04
Active, closed
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction
DrugDurvalumab
AstraZeneca
Phase 3
957
Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kochi, Kurume-shi
2020-11-17
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
DrugsSaruparib·Camizestrant·Datopotamab Deruxtecan·Trastuzumab deruxtecan
AstraZeneca
Phase 1/2
702
Chūōku, Kōtoku
2020-11-12
Active, closed
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
NCT04550260Esophageal Squamous Cell Carcinoma
DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin
AstraZeneca
Phase 3
640
Bunkyō City, Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku
2020-10-19
Active, closed
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
NCT04419532Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1
40
Chūōku, Kashiwa, Kōtoku
2020-10-09
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone
Acerta Pharma BV
Phase 3
611
Chiba, Chūōku, Fukuoka, Itabashi-ku, Kahoku-gun, Kashiwa, Kobe, Kōtoku
2020-10-08
Active, closed
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963Squamous Cell Carcinoma of the Head and Neck
DrugsMonalizumab·Cetuximab
AstraZeneca
Phase 3
370
Chūōku, Fukuoka, Hiroshima, Isehara-shi, Kashiwa, Kobe, Kōtoku, Okayama
2020-10-02
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Osimertinib
Janssen Research & Development, LLC
Phase 3
1,074
Bunkyō City, Chūōku, Fukuoka, Himeji, Hirakata, Kanazawa, Kashiwa, Kurume
2020-09-30
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Chūōku, Kashiwa, Suita-shi
2020-08-18
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel
AstraZeneca
Phase 3
866
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Gifu, Hidaka-shi, Hiroshima
2020-07-24
Active, closed
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
DrugsCapivasertib·Abiraterone acetate
AstraZeneca
Phase 3
1,012
Bunkyō City, Chiba, Chūōku, Fukuoka, Hamamatsu, Hirakata-shi, Hirosaki-shi, Isehara-shi
2020-07-13
Active, closed
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04379596Gastric Cancer
DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·5-FU
AstraZeneca
Phase 2
452
Chūōku, Kashiwa
2020-06-03
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
805
Chūōku, Kashiwa-shi, Kōtoku, Kurume-shi, Kyoto, Matsuyama, Minatoku, Nagoya
2020-05-05
Active, closed
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
NCT04325828Salivary Gland Neoplasms
DrugApalutamide
Janssen Pharmaceutical K.K.
Phase 2
31
Chūōku, Fukuoka, Hirakata, Matsuyama, Nagoya, Niigata, Sapporo
2020-04-07
Recruiting
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994Neoplasms, Child, Adolescent
DrugsRamucirumab·Vinorelbine·Abemaciclib·Temozolomide
Eli Lilly and Company
Phase 2
105
Chūōku, Fukuoka, Kobe
2020-01-22
Active, closed
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
NCT04170153Metastatic or Locally Advanced Unresectable Solid Tumors
DrugsTuvusertib·Niraparib
EMD Serono Research & Development Institute, Inc.
Phase 1
161
Chūōku, Kashiwa-shi
2019-12-20
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
701
Chūōku, Hirakata, Kashiwa, Kobe, Nagoya, Okayama, Shizuoka
2019-09-04
Active, closed
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
NCT03944772Non-Small Cell Lung Cancer
DrugsNecitumumab·Gefitinib·Selpercatinib·Savolitinib
AstraZeneca
Phase 2
247
Chūōku, Fukuoka, Kōtoku, Nagoya, Osaka, Wakayama
2019-06-25
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
2,517
Akita, Chiba, Chūōku, Hakodate, Hirosaki, Kanazawa, Kobe, Koshigaya
2019-06-11
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
DrugDurvalumab
AstraZeneca
Phase 3
810
Chūōku, Kashiwa, Kitaadachi-gun, Mitaka-shi, Osaka, Suita-shi, Wakayama, Yokohama
2019-04-16
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Chūōku, Habikino-shi, Kōtoku, Kurume-shi, Osaka, Sendai, Suita-shi
2019-03-22
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
DrugDurvalumab
AstraZeneca
Phase 3
724
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Kobe, Niigata
2019-03-06
Active, closed
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
NCT03775486Non-small Cell Lung Cancer NSCLC
DrugsOlaparib·Durvalumab·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 2
401
Chūōku, Kanazawa, Kurume-shi,, Matsuyama, Nagoya, Sendai, Sunto-gun, Ube-shi
2018-12-21
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
724
Bunkyō City, Chiba, Chūōku, Fukuoka, Hiroshima, Kurume-shi, Musashino-shi, Nagoya
2018-11-30
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
730
Bunkyō City, Chūōku, Fukuoka, Iwakuni-shi, Kashiwa, Kōtoku, Kurume-shi, Nagoya
2018-09-27
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,246
Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Kanazawa, Kita-gun, Koshigaya-shi, Kōtoku
2018-09-27
Active, closed
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
NCT03423628Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
DrugAZD1390
AstraZeneca
Phase 1
159
Chūōku, Hidaka-shi, Kyoto
2018-04-02
Active, closed
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
DrugDatopotamab Deruxtecan
Daiichi Sankyo Co., Ltd.
Phase 1
890
Nagoya, Koto-Ku, Shinagawa-Ku, Chūōku, Kashiwa
2018-01-31
Active, closed
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
NCT03252808Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
DrugsTS-1·Abraxane·Nab-paclitaxel·Gemcitabine
Takara Bio Inc.
Phase 1
36
Nagoya, Chiba, Kashiwa, Yokohama, Osaka, Chūōku, Koto-Ku
2017-09-25
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
DrugsAbraxane·Tremelimumab·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,186
Bunkyō City, Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku
2017-06-01
Active, closed
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT03043872Small Cell Lung Carcinoma Extensive Disease
DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin
AstraZeneca
Phase 3
987
Chūōku, Fukuoka, Fukushima, Himeji-shi, Iwakuni-shi, Kashiwa, Kōtoku, Kurume-shi
2017-03-27
Active, closed
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
NCT02609776Non-Small-Cell Lung Cancer
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
751
Chūōku, Hyōgo, Kashiwa, Kurume, Nagoya, Niigata, Osaka, Tokyo
2016-05-24
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
DrugApalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Chūōku, Hakata-Ku, Koshigaya, Matsuyama, Minamiku, Miyazaki, Nagano, Nagasaki
2015-11-27
Active, closed
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
NCT02519348Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab·Bevacizumab
MedImmune LLC
Phase 2
433
Chūōku, Kashiwa, Osakasayama-shi
2015-10-19
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Partner Therapeutics, Inc.
Phase 2
250
Chūōku, Kawasaki, Osaka, Tokyo
2015-01
Active, closed
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
NCT02143466Advanced Non Small Cell Lung Cancer
DrugsSavolitinib·Selumetinib·Osimertinib·Durvalumab
AstraZeneca
Phase 1
344
Chūōku, Habikino-shi, Hirakata-shi, Kashiwa, Nagoya
2014-08-05
Active, closed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Breast Cancer
DrugOlaparib
AstraZeneca
Phase 3
1,837
Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kashiwa
2014-04-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Osakasayama-shi, Sapporo
2013-09-03
Rows per page Showing 101–200 of 202
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-japan/city/ch-ku?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,472 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 202 of those studies with a site in Chūōku.

How many clinical trials are recruiting in Chūōku?

94 of the 202 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 0 have not yet opened recruitment, 108 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.